LUYE PHARMA's stock surged 5.17% during intraday trading on Thursday, reflecting strong investor sentiment.
The sharp rise follows the company's release of its 2025 earnings report, which showed significant profit growth. Revenue increased by 4.1% year-on-year to RMB 6.308 billion, while profit attributable to shareholders jumped 31.12% to approximately RMB 619 million. The company attributed the revenue growth to higher sales and increased licensing income from certain products.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments